<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204726">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000244</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-08067-1</org_study_id>
    <secondary_id>R01DA008067</secondary_id>
    <secondary_id>R01-08067-1</secondary_id>
    <nct_id>NCT00000244</nct_id>
  </id_info>
  <brief_title>Effects of Dynorphin 1-13 on Heroin Addiction - 1</brief_title>
  <official_title>Effects of Dynorphin 1-13 on Heroin Addiction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of IV dynorphin in humans during acute
      heroin abstinence, in order to determine that dynorphin suppresses acute opiate withdrawal,
      reduces opiate craving, and is safe at doses required to produce the above effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized double blinded study of the effects of a single IV dose of dynorphin A 1-13 on
      heroin withdrawal in human opiate addicts
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1994</start_date>
  <completion_date type="Actual">March 1997</completion_date>
  <primary_completion_date type="Actual">March 1997</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Craving scale</measure>
  </primary_outcome>
  <enrollment>0</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <condition>Substance Withdrawal Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dynorphin 1 - 13</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        opiate addict between the ages of 18-55

        Exclusion Criteria:

        Regular abuse of other drugs, unstable medical conditions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Pentel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U of Minnesota School of Medicine</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Specker S, Wananukul W, Hatsukami D, Nolin K, Hooke L, Kreek MJ, Pentel PR. Effects of dynorphin A(1-13) on opiate withdrawal in humans. Psychopharmacology (Berl). 1998 Jun;137(4):326-32.</citation>
    <PMID>9676891</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 26, 2015</lastchanged_date>
  <firstreceived_date>September 20, 1999</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>addiction</keyword>
  <keyword>opiate</keyword>
  <keyword>heroin</keyword>
  <keyword>dynorphin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heroin Dependence</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dynorphins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
